Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19,283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.
Kikuchi T, Tsukada N, Kunisada K, Matsumoto C, Nomura-Yogo M, Oda Y, Sato K, Takei T, Ogura M, Abe Y, Suzuki K, Hosoya O, Ishida T. Kikuchi T, et al. Among authors: suzuki k. Ann Hematol. 2024 Jun 6. doi: 10.1007/s00277-024-05835-4. Online ahead of print. Ann Hematol. 2024. PMID: 38839622 No abstract available.
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K, Yasuda Y, Ando M, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Hase T, Nishio N, Mori S, Shimokata T, Sano T, Niimi K, Yoshikawa N, Akamatsu S, Ando Y, Akiyama M, Sone M, Ishii M, Arima H. Kobayashi T, et al. Among authors: suzuki k. Cancer Immunol Immunother. 2024 Jun 4;73(8):146. doi: 10.1007/s00262-024-03733-2. Cancer Immunol Immunother. 2024. PMID: 38833157
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S; DREAMM-8 Investigators. Dimopoulos MA, et al. Among authors: suzuki k. N Engl J Med. 2024 Jun 2. doi: 10.1056/NEJMoa2403407. Online ahead of print. N Engl J Med. 2024. PMID: 38828951
Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.
Sumi T, Sekikawa M, Koshino Y, Nagayama D, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Suzuki K, Ikeda T, Michimata H, Watanabe H, Yamada Y, Osuda K, Tanaka Y, Chiba H. Sumi T, et al. Among authors: suzuki k. Thorac Cancer. 2024 Jun 3. doi: 10.1111/1759-7714.15385. Online ahead of print. Thorac Cancer. 2024. PMID: 38828610 Free article.
19,283 results
You have reached the last available page of results. Please see the User Guide for more information.